IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Immunome Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Aug 11, 2026
$16.77+0.30 (+1.82%)
Close on Oct 19, 2026
- Market cap
- $1.90B
- P/E (TTM)
- –
- Dividend yield
- –
Immunome Inc. income statement
Ratios
Latest available, balances at Mar 31, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -5947.9%
- Net margin
- -5593.8%
- Return on equity, FY2025
- -52.1%
Financial strength
- Current ratio
- 21.68
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 2125.7%
Valuation
- P/E ratio
- –
- Price to sales
- 472.55
- Price to book
- 3.22
- Dividend yield
- –